ESCaping rejection: A step forward for embryonic-stem-cell-based regenerative medicine

Tim Willinger; Richard A Flavell

doi:10.1016/j.stem.2013.12.003

ESCaping rejection: A step forward for embryonic-stem-cell-based regenerative medicine

Cell Stem Cell. 2014 Jan 2;14(1):3-4. doi: 10.1016/j.stem.2013.12.003.

Authors

Tim Willinger¹, Richard A Flavell²

Affiliations

¹ Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06520, USA.
² Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06520, USA; Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, CT 06520, USA. Electronic address: richard.flavell@yale.edu.

PMID: 24388169
DOI: 10.1016/j.stem.2013.12.003

Abstract

The use of human embryonic stem cells (hESCs) for regenerative medicine currently faces several hurdles, including immune rejection of transplanted cells. Now in Cell Stem Cell, Rong et al. (2014) describe a strategy to protect hESCs from immune rejection while avoiding systemic immunosuppression, potentially facilitating clinical implementation of hESC-based therapies.

Publication types

Comment

MeSH terms

Animals
Cell Differentiation*
Cell- and Tissue-Based Therapy*
Embryonic Stem Cells / cytology*
Embryonic Stem Cells / immunology*
Graft Rejection / prevention & control*
Humans
Immunosuppression Therapy*